Page last updated: 2024-11-04

bay h 4502

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2378
CHEMBL ID277535
CHEBI ID78692
SCHEMBL ID36803
MeSH IDM0111349

Synonyms (154)

Synonym
AC-15414
STK618771
1-[biphenyl-4-yl(phenyl)methyl]-1h-imidazole
MLS001074074
AKOS005553008
HMS3393F04
AB00383029-16
BRD-A94543220-001-02-3
MLS000028576 ,
bay-h-4502
amycor
azolmen
1h-imidazole, 1-((1,1'-biphenyl)-4-ylphenylmethyl)-
imidazole, 1-(alpha-(4-biphenylyl)benzyl)-
bifonazol
einecs 262-336-6
bifonazol [inn-spanish]
trifonazole
brn 0618427
bay h-4502
1h-imidazole, 1-((1,1'-biphenyl)-4-ylphenylmethyl)-, (+-)-
bifonazolum [inn-latin]
1-[phenyl-(4-phenylphenyl)methyl]imidazole
(+-)1-([1,1'-biphenyl]-4-ylphenylmethyl)-1h-imidazole
bifonazole
60628-96-8
mycospor
bay h 4502
MLS000759537
cpd000058970
1-[biphenyl-4-yl(phenyl)methyl]imidazole
1-(alpha-(4-biphenylyl)benzyl)imidazole
DB04794
1-(p,alpha-diphenylbenzyl)imidazole
(+-)-1-(p,alpha-diphenylbenzyl)imidazole
1-((4-biphenylyl)phenylmethyl)-1h-imidazole
D01775
mycospor (tn)
bifonazole (jp17/usan/inn)
BSPBIO_003570
NCGC00089815-03
NCGC00089815-02
smr000058970
KBIO3_002922
SPECTRUM2_000035
SPBIO_000129
SPECTRUM3_001970
SPECTRUM1505309
NCGC00089815-04
1-((4-biphenylyl)-phenylmethyl)-1h-imidazole
HMS2051F04
HMS2090K13
HMS2093B09
VU0239694-7
1-(biphenyl-4-yl-phenyl-methyl)-1h-imidazole
1-(biphenyl-4-yl-phenyl-methyl)-1h-imidazole (bifonazole)
cid_2378
1-(1-biphenyl-4-yl-2-phenyl-methyl)-1h-imidazole
1-(biphenyl-4-yl-phenyl-methyl)-1h-imidazole(bifonazole)
bdbm50128548
1-(biphenyl-4-yl-phenyl-methyl)-1h-imidazole( bifanozole)
nsc-758954
CHEMBL277535 ,
chebi:78692 ,
d01ac10
FT-0652733
HMS1922B18
NCGC00018254-03
1-[phenyl-(4-phenylphenyl)methyl]imidazole;bifonazole
A832816
NCGC00018254-04
NCGC00018254-02
NCGC00018254-05
1h-imidazole, 1-([1,1'-biphenyl]-4-ylphenylmethyl)-
BCP9000410
nsc758954
MLS001424050
pharmakon1600-01505309
cas-60628-96-8
dtxsid9045631 ,
tox21_110850
dtxcid7025631
bifonazolum
HMS2232J24
CCG-39996
CCG-100993
unii-qyj305z91o
qyj305z91o ,
5-23-04-00292 (beilstein handbook reference)
nsc 758954
bifonazole [usan:inn:ban:jan]
AB07497
S1854
HMS3374H02
DL-338
HY-B0301
NC00243
SCHEMBL36803
NCGC00018254-08
tox21_110850_1
KS-5111
bifonazole [ep monograph]
bifonazole [who-dd]
bifonazole [jan]
bifonazole [usan]
1h-imidazole, 1-((1,1'-biphenyl)-4-ylphenylmethyl)-, (+/-)-
bifonazole [inn]
(+/-)-1-(p,.alpha.-diphenylbenzyl)imidazole
bifonazole [mart.]
bifonazole [ep impurity]
bifonazole [mi]
(biphenyl-4-yl)-imidazol-1-yl-phenylmethane
1-[alpha-(4-biphenylyl)-benzyl]-imidazole
Q-200717
1-([1,1'-biphenyl]-4-yl(phenyl)methyl)-1h-imidazole
bedriol
1h-imidazole, 1-([1,1'-biphenyl]-4-ylphenylmethyl)-, (.+/-.)-
(.+/-.)-1-(p,.alpha.-diphenylbenzyl)imidazole
imidazole, 1-(.alpha.-(4-biphenylyl)benzyl)-
(.+/-.)-bifonazole
1-(.alpha.-(4-biphenylyl)benzyl)imidazole
mycosporan
1-[[1,1'-biphenyl]-4-yl(phenyl)methyl]-1h-imidazole #
1-(alpha,4-diphenylbenzyl)imidazole
B4173
OPERA_ID_1656
AB00383029_18
AB00383029_17
mfcd00865567
1-[phenyl(4-phenylphenyl)methyl]-1h-imidazole
bifonazole, european pharmacopoeia (ep) reference standard
bifonazole, >=98% (hplc)
HMS3651G21
bifonazole, pharmaceutical secondary standard; certified reference material
bifonazole for system suitability, european pharmacopoeia (ep) reference standard
sr-01000003136
SR-01000003136-4
SR-01000003136-6
SBI-0206755.P001
MRF-0000274
HMS3715L21
SW197623-3
BCP22297
Q421162
bifonazole,(s)
1-(biphenyl-4-yl(phenyl)methyl)-1h-imidazole
BRD-A94543220-001-12-2
NCGC00018254-09
AMY32554
bifonazole for system suitability
BP164253
1-({[1,1'-biphenyl]-4-yl}(phenyl)methyl)-1h-imidazole
EN300-295624
Z275375166

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The number of patients with at least one adverse event was twice as high in the bifonazole-urea group in comparison to the 40% urea ointment with plastic dressing group."( Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized e
Baran, R; Bulai-Livideanu, C; Coubetergues, H; Lahfa, M; Ortonne, JP; Paul, C; Piraccini, BM; Richert, B; Sibaud, V; Szepietowski, JC; Tosti, A; Voisard, JJ, 2013
)
0.39
" Two groups of patients recovered well with a low incidence of adverse reactions in the treatment, and the overall curative effect was good with the inter-group difference at P>0."( Analysis on curative effects and safety of 2% liranaftate ointment in treating tinea pedis and tinea corporis & cruris.
Abliz, P; Dong, X; Fan, J; Kasimu, H; Sulaiman, A; Upur, H; Wan, X; Wang, X; Zhang, L, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" The developed analytical procedure is useful in pharmacokinetic studies with bifonazole."( [Determination of bifonazole using HPLC in pharmacokinetic studies].
Agapitova, IV; Arzamastsev, AP; Dombrovskiĭ, VS; Firsov, AA; Gagaeva, EV; Kadenatsi, IB; Kuleshova, EE; Salib, I; Shustova, LV, 1996
)
0.29
" Furthermore, the pharmacokinetic profile of the sesquiterpene lactones was investigated using computational methods."( Sesquiterpene lactones from Anthemis melanolepis and their antibacterial and cytotoxic activities. Prediction of their pharmacokinetic profile.
Dimas, K; Karioti, A; Koukoulitsa, C; Rancic, A; Saroglou, V; Skaltsa, H; Zervou, M, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
"A parallel-group double-blind study was carried out which compared the efficacy of chemical avulsion of affected nail by urea 40% and bifonazole 1% cream alone with that of the same local therapy combined with short-term oral griseofulvin in onychomycosis."( Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin.
Bergman, R; Bitterman, O; Cohen, A; Friedman-Birnbaum, R; Shemer, A; Stettendorf, S, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
" Another very important prerequisite for systematic treatment is the removal of as much fungus-infected nail material as possible, or else bioavailability at the site of infection cannot, or only hardly, be guaranteed."( Non-traumatic removal of the nail and simultaneous treatment of onychomycosis.
Nolting, S, 1984
)
0.27
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The proposed HPLC methods are applied to the analysis of commercial dosage forms (creams) with solid-phase extraction (SPE) procedure, using a diol sorbent, being found to be a convenient technique for the sample preparation giving quantitative drug recovery."( HPLC analysis of imidazole antimycotic drugs in pharmaceutical formulations.
Andrisano, V; Cavrini, V; Di Pietra, AM; Gatti, R,
)
0.13
" Topical bifonazole in our experience did not demonstrate any morphological effect on sebaceous gland and hair even when applied in the dosage of 3 mg/cm2/day."( Lack of antiandrogenic effects of topical bifonazole on sebaceous glands and hairs in the hamster flank organ.
Aricò, M; Bongiorno, MR; Noto, G; Pravatà, G, 1993
)
0.29
" Study B: More subjects adhered to amorolfine dosage (81."( Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Sarkany, M; Schaller, M; Sigurgeirsson, B, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (105)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency27.55120.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency25.05940.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency25.11890.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency47.39355.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency29.63210.007215.758889.3584AID588342
acetylcholinesteraseHomo sapiens (human)Potency38.90180.002541.796015,848.9004AID1347397
phosphopantetheinyl transferaseBacillus subtilisPotency19.95260.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency24.38223.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency14.40750.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency29.09290.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency21.55990.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency10.13850.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency13.10130.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency25.32110.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency15.64980.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency1.25890.00137.762544.6684AID914; AID915
PINK1Homo sapiens (human)Potency50.11872.818418.895944.6684AID624263
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency30.04740.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency10.59670.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency5.95570.000417.946075.1148AID1346795
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency70.79466.309627.099079.4328AID602179
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.01230.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency4.46680.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency25.32450.000214.376460.0339AID720691; AID720692; AID720719
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.61420.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.39330.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency20.18720.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency23.71010.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.68130.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency0.02450.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency0.24550.00108.379861.1304AID1645840
glucocerebrosidaseHomo sapiens (human)Potency16.19360.01268.156944.6684AID2101
ParkinHomo sapiens (human)Potency50.11870.819914.830644.6684AID624263
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency22.53580.707936.904389.1251AID504333
shiga toxin 1 variant A subunitEscherichia coli O157:H7Potency7.98055.035416.193232.6037AID2320
shiga toxin 1 B subunitEscherichia coli O157:H7Potency7.98055.035413.848822.4921AID2320
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency26.60110.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency29.84700.001019.414170.9645AID743191
IDH1Homo sapiens (human)Potency20.59620.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.63160.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency3.08360.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.74980.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.60320.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency8.73660.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency13.448119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency22.61420.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency21.97410.039147.5451146.8240AID1224845
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency19.95260.316212.443531.6228AID902
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency39.81073.548119.542744.6684AID743266
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency26.33340.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency20.57450.042027.378961.6448AID743210; AID743228
mitogen-activated protein kinase 1Homo sapiens (human)Potency24.06820.039816.784239.8107AID1454; AID995
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency25.11890.65619.452025.1189AID927
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
eyes absent homolog 2 isoform aHomo sapiens (human)Potency25.11891.199814.641950.1187AID488837
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency14.50800.000627.21521,122.0200AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency11.22020.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency14.48420.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency18.30110.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.10000.031610.279239.8107AID884; AID885
neuropeptide S receptor isoform AHomo sapiens (human)Potency15.84890.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency0.02450.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.02450.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency2.51190.56239.398525.1189AID652106
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency31.62280.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency25.11891.584913.004325.1189AID927
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency3.16231.000010.475628.1838AID1457
TAR DNA-binding protein 43Homo sapiens (human)Potency6.30961.778316.208135.4813AID652104
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency22.38723.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.02450.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.02450.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
calpain II, partialSus scrofa (pig)IC50 (µMol)14.70601.77424.93387.7087AID1420
phospholipase A2 precursorHomo sapiens (human)IC50 (µMol)8.89001.02009.002515.2000AID588400
cysteine protease ATG4B isoform aHomo sapiens (human)IC50 (µMol)8.50001.250010.663219.1000AID504756
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)27.10000.11007.190310.0000AID1473738
Steroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)IC50 (µMol)0.79000.00200.98184.7300AID362471
Steroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)Ki0.05650.03800.39691.6250AID53377
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)23.00000.05373.075710.0000AID1184068
Lanosterol 14-alpha demethylaseHomo sapiens (human)IC50 (µMol)0.34200.05001.43904.0000AID322753
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)AC501.06400.19503.667918.6960AID540270
heat shock protein 90, putativePlasmodium falciparum 3D7AC501.06900.19504.992098.5000AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (364)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
steroid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
androgen biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
glucocorticoid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
sex differentiationSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
steroid metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
hormone biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
progesterone metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
steroid biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol metabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein catabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein secretionLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of amyloid-beta clearanceLanosterol 14-alpha demethylaseHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (124)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
steroid 17-alpha-monooxygenase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
iron ion bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
oxygen bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
heme bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
17-alpha-hydroxyprogesterone aldolase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
iron ion bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol 14-demethylase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
heme bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenLanosterol 14-alpha demethylaseHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (73)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
endoplasmic reticulum membraneSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
axonSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
neuronal cell bodySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
endoplasmic reticulum membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (351)

Assay IDTitleYearJournalArticle
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID416230Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at dermis at ED50 after 4 days by Uvitex-2B staining-based fluorescence mi2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID49117Tested In vitro for antifungal activity at pH 5.82002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID633957Antifungal activity against Candida albicans isolated from human after 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID4911150% inhibitory activity against Candida albicans (40 clinical isolates) determined at pH-5.81995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID167335Topical comparison with bifonazole in white male rabbits at 1% concentration of compound1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1104302Antifungal activity against Aspergillus flavus ATCC 9643 at 28 degC measured after 72 hr by microdilution method2010Chemical & pharmaceutical bulletin, Feb, Volume: 58, Issue:2
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID48250Inhibitory activity against Candida. species. (40 clinical isolates), determined at pH-7.21995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID416040Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID1411642Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by serial dilution method
AID1721984Antifungal activity Aspergillus niger by microdilution method2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID416226Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at hypodermis at twofold ED90 after 4 days by Uvitex-2B staining-based flu2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID416232Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at dermis at twofold ED90 after 4 days by Uvitex-2B staining-based fluores2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID321421Antifungal activity against Aspergillus ochraceus ATCC 12066 after 72 hrs by microdilution test2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID723711Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial dilution technique2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1104303Antifungal activity against Aspergillus niger ATCC 6275 at 28 degC measured after 72 hr by microdilution method2010Chemical & pharmaceutical bulletin, Feb, Volume: 58, Issue:2
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID49122Compound was tested for its anti-candida activity, expressed as ratio of minimum inhibitory concentration2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID416223Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at hypodermis at ED50 after 4 days by Uvitex-2B staining-based fluoresc2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID1411639Fungicidal activity against Aspergillus ochraceus ATCC 12066 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs and measured after 72 hrs by serial dilution method
AID1596687Fungicidal activity against Aspergillus versicolor ATCC 11730 incubated for 72 hrs followed by sub-culturing on broth malt medium and measured after 72 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID1412937Antifungal activity against Aspergillus ochraceus by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID644193Antifungal activity against Aspergillus flavus ATCC 9643 treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID416234Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at hypodermis at ED90 after 4 days by Uvitex-2B staining-based fluorescenc2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID601258Antifungal activity against Aspergillus niger using 1 x 10'5 spore/100 uL assessed as 99.5% fungal killing of original inoculum after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID1399507Antifungal activity against Aspergillus fumigatus isolate 1022 after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID1596685Fungicidal activity against Aspergillus fumigatus ATCC 1022 incubated for 72 hrs followed by sub-culturing on broth malt medium and measured after 72 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID416224Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at hypodermis at ED90 after 4 days by Uvitex-2B staining-based fluoresc2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID1184070Inhibition of mouse IDO1 expressed in mouse P815B cells using L-tryptophan substrate incubated for 18 hrs by HPLC based cellular assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID600767Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial dilution method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID1411634Antifungal activity against Aspergillus versicolor ATCC 11730 after 72 hrs by serial dilution method
AID723705Fungicidal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial subcultivation method2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID45508Inhibitory activity against Candida albicans (40 clinical isolates), determined at pH-7.21995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID723706Antifungal activity against Aspergillus flavus ATCC 9643 after 72 hrs by serial dilution technique2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID464059Antibacterial activity against Proteus mirabilis clinical isolate after 48 hrs by serial dilution technique2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Sesquiterpene lactones from Anthemis melanolepis and their antibacterial and cytotoxic activities. Prediction of their pharmacokinetic profile.
AID1412942Fungicidal activity against Penicillium funiculosum ATCC 36839 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID456073Antifungal activity against Fulvia fulva TK 5318 after 72 hrs by serial sub-cultivation method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1399522Fungicidal activity against Candida albicans after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID600769Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by serial dilution method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID644185Antifungal activity against Aspergillus flavus ATCC 9643 after 72 hrs by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID633962Antifungal activity against Penicillium funiculosum ATCC 36839 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID1596692Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by microdilution technique2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID1596689Fungicidal activity against Aspergillus ochraceus ATCC 12066 incubated for 72 hrs followed by sub-culturing on broth malt medium and measured after 72 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID600778Fungicidal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID600773Fungicidal activity against Aspergillus ochraceus ATCC 12066 after 72 hrs2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID600775Fungicidal activity against Aspergillus niger ATCC 6275 after 72 hrs2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID601253Antifungal activity against Aspergillus flavus using 1 x 10'5 spore/100 uL after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID723704Fungicidal activity against Trichoderma viride IAM 5061 after 72 hrs by serial subcultivation method2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID48259Resistance against all Candida. species (40 clinical isolates) at 256 micro g/mL (pH=5.8). Activity is expressed as R%.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID416229Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at epidermis at twofold ED90 after 4 days by Uvitex-2B staining-based fluo2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID1399519Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID48432Tested In vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 7.22002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1399521Antifungal activity against Candida albicans after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID416221Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at dermis at ED90 after 4 days by Uvitex-2B staining-based fluorescence2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID1412939Antifungal activity against Trichoderma viride IAM 5061 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID45507Inhibitory activity against Candida albicans (40 clinical isolates), determined at pH-5.81995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID1412936Antifungal activity against Aspergillus versicolor ATCC 11730 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1399514Fungicidal activity against Aspergillus niger ATCC 6275 after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID600771Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial dilution method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID1411641Fungicidal activity against Aspergillus niger ATCC 6275 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs and measured after 72 hrs by serial dilution method
AID1721986Antifungal activity Penicillium funiculosum by microdilution method2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID1596691Fungicidal activity against Aspergillus niger ATCC 6275 incubated for 72 hrs followed by sub-culturing on broth malt medium and measured after 72 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID1721983Antifungal activity Aspergillus ochraceus by microdilution method2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID48271Tested In vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 7.22002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID48249Inhibitory activity against Candida. species. (40 clinical isolates), determined at pH-5.81995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID46898In vitro antimycotic activity of compound against Candida albicans was determined as -log MIC90 compound to that of -log MIC90 bifonazole1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study.
AID633961Antifungal activity against Aspergillus flavus ATCC 9643 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID416218Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at epidermis at ED90 after 4 days by Uvitex-2B staining-based fluoresce2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID601257Antifungal activity against Drechslera australiensis using 1 x 10'5 spore/100 uL after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID464058Antifungal activity against Candida albicans clinical isolate after 48 hrs by serial dilution technique2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Sesquiterpene lactones from Anthemis melanolepis and their antibacterial and cytotoxic activities. Prediction of their pharmacokinetic profile.
AID48251Inhibitory activity against Candida. species (40 clinical isolates), determined at pH-5.81995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID1184069Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins in presence of 0.01% Triton-X by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1399520Fungicidal activity against Penicillium ochrochloron ATCC 9112 after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID416222Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at dermis at twofold ED90 after 4 days by Uvitex-2B staining-based fluo2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID644184Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID633954Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID723701Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial dilution technique2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID1104300Antifungal activity against Passalora fulva TK5318 at 28 degC measured after 72 hr by microdilution method2010Chemical & pharmaceutical bulletin, Feb, Volume: 58, Issue:2
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID644183Antifungal activity against Aspergillus fumigatus human isolate after 72 hrs by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID321425Antifungal activity against Aspergillus flavus ATCC 9643 after 72 hrs by microdilution test2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID723702Fungicidal activity against Aspergillus fumigatus after 72 hrs by serial subcultivation method2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID1411645Fungicidal activity against Penicillium funiculosum ATCC 36839 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs and measured after 72 hrs by serial dilution method
AID49127Tested In vitro for antifungal activity at pH 5.82002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID600776Fungicidal activity against Aspergillus fumigatus plant isolate after 72 hrs2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID1596693Fungicidal activity against Trichoderma viride IAM 5061 incubated for 72 hrs followed by sub-culturing on broth malt medium and measured after 72 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID49292Tested In vitro for antifungal activity at pH 5.82002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1104304Antifungal activity against Hypocrea rufa IAM 5061 at 28 degC measured after 72 hr by microdilution method2010Chemical & pharmaceutical bulletin, Feb, Volume: 58, Issue:2
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID644195Antifungal activity against Fulvia fulva treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID416228Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at epidermis at ED90 after 4 days by Uvitex-2B staining-based fluorescence2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID49431In vitro antifungal activity against 40 strains at pH 5.8,(percent of resistant species at 256 ug/mL)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1411617Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial dilution method
AID633956Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID601255Antifungal activity against Trichoderma viride using 1 x 10'5 spore/100 uL after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID1104307Antifungal activity against Talaromyces funiculosus ATCC 36839 at 28 degC measured after 72 hr by microdilution method2010Chemical & pharmaceutical bulletin, Feb, Volume: 58, Issue:2
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID1411636Fungicidal activity against Aspergillus fumigatus incubated for 72 hrs followed by serial sub-cultivation for 72 hrs and measured after 72 hrs by serial dilution method
AID456072Antifungal activity against Fulvia fulva TK 5318 after 72 hrs by serial dilution method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1721990Fungicidal activity Aspergillus versicolor2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID1399512Fungicidal activity against Aspergillus ochraceus ATCC 12066 after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID4825250% inhibitory activity against the Candida. species (40 clinical isolates) was determined at pH-7.21995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID1399509Antifungal activity against Aspergillus versicolor ATCC 11730 after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID601259Antifungal activity against Aspergillus flavus using 1 x 10'5 spore/100 uL assessed as 99.5% fungal killing of original inoculum after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID1412938Antifungal activity against Aspergillus niger by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1399511Antifungal activity against Aspergillus ochraceus ATCC 12066 after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID1104306Antifungal activity against Penicillium ochrochloron ATCC 9112 at 28 degC measured after 72 hr by microdilution method2010Chemical & pharmaceutical bulletin, Feb, Volume: 58, Issue:2
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID416041Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID321423Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by microdilution test2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID1104305Antifungal activity against plant isolate Aspergillus fumigatus at 28 degC measured after 72 hr by microdilution method2010Chemical & pharmaceutical bulletin, Feb, Volume: 58, Issue:2
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID723708Antifungal activity against Aspergillus fumigatus after 72 hrs by serial dilution technique2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID48431Tested In vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 5.82002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID633964Antifungal activity against Trichoderma viride IAM 5061 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID245660In vitro minimal inhibitory concentration against Candida albicans with percentage of resistant strains %R = 10 (MIC > 64 ug/mL) at a range of 0.5-8 ug/mL2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
AID633960Antifungal activity against Aspergillus niger ATCC 6275 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID600770Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial dilution method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID1412941Antifungal activity against Penicillium ochrochloron ATCC 9112 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID600766Antifungal activity against Aspergillus versicolor ATCC 11730 after 72 hrs by serial dilution method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID27580Partition coefficient (logP)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID644190Antifungal activity against Trichoderma viride IAM 5061 treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID633953Antifungal activity against Aspergillus flavus ATCC 9643 after 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1411644Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial dilution method
AID48266Tested In vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 7.22002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1412950Fungicidal activity against Penicillium verrucosum var. cyclopium food isolate by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412935Antifungal activity against Aspergillus fumigatus ATCC 1022 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID321422Antifungal activity against Aspergillus versicolor ATCC 11730 after 72 hrs by microdilution test2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID200310Tested for antifungal activity against Saccharomyces cerevisiae ATCC 28 383 after 48 hr incubation2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Stereoselective synthesis of 7 alpha- and 7 beta-aminocholestanol as potent fungicidal drugs.
AID1399517Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID601263Antifungal activity against Drechslera australiensis using 1 x 10'5 spore/100 uL assessed as 99.5% fungal killing of original inoculum after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID49113In vitro antifungal activity against 40 strains at pH 7.22002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID321424Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by microdilution test2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID1412940Antifungal activity against Penicillium funiculosum ATCC 36839 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID48926Tested for antifungal activity against Candida albicans CIP 1180-79 after 48 h incubation2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Stereoselective synthesis of 7 alpha- and 7 beta-aminocholestanol as potent fungicidal drugs.
AID456839Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by serial sub-cultivation method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID600779Fungicidal activity against Penicillium funiculosum ATCC 36839 after 72 hrs2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1104301Antifungal activity against Aspergillus versicolor ATCC 11730 at 28 degC measured after 72 hr by microdilution method2010Chemical & pharmaceutical bulletin, Feb, Volume: 58, Issue:2
Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID321420Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by microdilution test2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.
AID1184068Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID644186Antifungal activity against Aspergillus versicolor ATCC 11730 after 72 hrs by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID1184072Cytotoxicity against mouse P815B cells after 24 hrs by MTS/PMS assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID48925Tested In vitro for antifungal activity at pH 5.82002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID416227Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at epidermis at ED50 after 4 days by Uvitex-2B staining-based fluorescence2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID48270Tested In vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 5.82002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1721995Fungicidal activity Penicillium ochrochloron2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID644182Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID1596694Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by microdilution technique2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID456071Antifungal activity against Aspergillus flavus ATCC 9643 after 72 hrs by serial sub-cultivation method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID644189Antifungal activity against Penicillium ochrochloron ATCC 9112 treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID19427HPLC capacity factor (k)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID1721985Antifungal activity Trichoderma viride by microdilution method2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID49121Inhibitory activity against the Candida albicans (40 clinical isolates), determined at pH-7.21995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID1721982Antifungal activity Aspergillus versicolor by microdilution method2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID416231Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at dermis at ED90 after 4 days by Uvitex-2B staining-based fluorescence mi2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID774657Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi infected in mouse NIH/3T3 cells after 48 hrs by Hoechst staining assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID456069Antifungal activity against Aspergillus versicolor ATCC 11730 after 72 hrs by serial sub-cultivation method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1411638Antifungal activity against Aspergillus ochraceus ATCC 12066 after 72 hrs by serial dilution method
AID1721988Antifungal activity Penicillium verrucosum var. cyclopium by microdilution method2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID49123In vitro antifungal activity against 40 strains at pH 7.22002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID46897In vitro antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 5.8,(percent of resistant species at 256 ug/mL)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1412949Fungicidal activity against Penicillium ochrochloron ATCC 9112 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1596695Fungicidal activity against Penicillium ochrochloron ATCC 9112 incubated for 72 hrs followed by sub-culturing on broth malt medium and measured after 72 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID29421Partition coefficient (logP) (HPLC)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID1399515Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID456841Antifungal activity against Aspergillus fumigatus clinical isolate after 72 hrs by serial sub-cultivation method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID601252Antifungal activity against Aspergillus niger using 1 x 10'5 spore/100 uL after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID600768Antifungal activity against Aspergillus fumigatus plant isolate after 72 hrs by serial dilution method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID1721981Antifungal activity Aspergillus fumigatus by microdilution method2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID1184075Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1411640Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial dilution method
AID633963Antifungal activity against Penicillium ochrochloron ATCC 9112 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID1411648Fungicidal activity against Candida albicans incubated for 72 hrs followed by serial sub-cultivation for 72 hrs and measured after 72 hrs by serial dilution method
AID456838Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by serial dilution method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1596688Antifungal activity against Aspergillus ochraceus ATCC 12066 after 72 hrs by microdilution technique2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID48275Tested In vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 5.82002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID48276Tested In vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 7.22002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID48256Inhibitory activity against Candida. species (40 clinical isolates), determined at pH-5.81995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID456840Antifungal activity against Aspergillus fumigatus clinical isolate after 72 hrs by serial dilution method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID1399524Fungicidal activity against Penicillium cyclopium var verucosum after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID1484691Antileishmanial activity against Leishmania infantum chagasi MHOM/BR/1972/LD promastigote forms infected in golden hamster after 48 hrs by Alamar Blue assay2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID48260Percent resistance against all Candida. species (40 clinical isolates) at 256 micro g/mL (pH=7.2), activity is expressed as R%.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID723707Fungicidal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial subcultivation method2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID456834Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial dilution method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID456842Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial dilution method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1412944Fungicidal activity against Aspergillus niger by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1412946Fungicidal activity against Aspergillus versicolor ATCC 11730 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID49262Percent resistance against Candida albicans (40 clinical isolates) at 256 micro g/mL (pH=5.8), activity is expressed as R%.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID1596686Antifungal activity against Aspergillus versicolor ATCC 11730 after 72 hrs by microdilution method2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID416219Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at epidermis at twofold ED90 after 4 days by Uvitex-2B staining-based f2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID1411637Fungicidal activity against Aspergillus versicolor ATCC 11730 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs and measured after 72 hrs by serial dilution method
AID53377In vitro inhibition of human Cytochrome P450 17A1 activity2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
AID633955Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID723700Fungicidal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial subcultivation method2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID633951Antifungal activity against Aspergillus fumigatus isolated from human after 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID644180Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID362471Inhibition of human CYP17 expressed in Escherichia coli coexpressed with cytochrome P450 reductase2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
AID1596697Fungicidal activity against Penicillium funiculosum ATCC 36839 incubated for 72 hrs followed by sub-culturing on broth malt medium and measured after 72 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID723709Antifungal activity against Trichoderma viride IAM 5061 after 72 hrs by serial dilution technique2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID1412943Fungicidal activity against Trichoderma viride IAM 5061 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1596698Antifungal activity against Penicillium verrucosum var. cyclopium food isolate after 72 hrs by microdilution technique2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID633952Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1412948Antifungal activity against Penicillium verrucosum var. cyclopium food isolate by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID1484693Cytotoxicity against mouse NCTC-929 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay2017European journal of medicinal chemistry, Jul-28, Volume: 135An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID49120Inhibitory activity against the Candida albicans (40 clinical isolates), determined at pH-5.81995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID456070Antifungal activity against Aspergillus flavus ATCC 9643 after 72 hrs by serial dilution method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID633965Antifungal activity against Candida albicans isolated from human incubated for 72 hrs followed by serial sub-cultivation for 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID1412947Fungicidal activity against Aspergillus fumigatus ATCC 1022 by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID600774Fungicidal activity against Aspergillus versicolor ATCC 11730 after 72 hrs2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID644194Antifungal activity against Aspergillus versicolor ATCC 11730 treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID601261Antifungal activity against Trichoderma viride using 1 x 10'5 spore/100 uL assessed as 99.5% fungal killing of original inoculum after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID1596696Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by microdilution technique2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID1721992Fungicidal activity Aspergillus niger2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID1412945Fungicidal activity against Aspergillus ochraceus by microdilution method2018MedChemComm, May-01, Volume: 9, Issue:5
Design, synthesis and antimicrobial activity of usnic acid derivatives.
AID633950Antifungal activity against Aspergillus ochraceus ATCC 12066 after 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID456837Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial sub-cultivation method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1399508Fungicidal activity against Aspergillus fumigatus isolate 1022 after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID416220Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at dermis at ED50 after 4 days by Uvitex-2B staining-based fluorescence2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID600780Fungicidal activity against Fusarium sporotrichioides IMT 496 after 72 hrs2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID249367In vitro concentration causing 90% inhibition of Candida albicans with percentage of resistant strains %R = 10 (MIC > 64 ug/mL) at a range of 0.5-8 ug/mL2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
AID1721993Fungicidal activity Trichoderma viride2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID1596699Fungicidal activity against Penicillium verrucosum var. cyclopium food isolate incubated for 72 hrs followed by sub-culturing on broth malt medium and measured after 72 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID723710Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial dilution technique2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID4825790% inhibitory activity against the Candida. species (40 clinical isolates) was determined at pH-7.21995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID45343In vitro antifungal activity against 40 strains at pH 7.22002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID644181Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID1495983Inhibition of fungal keratinase activity at 10 mg/ml relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Efficiency of newly prepared thiazole derivatives against some cutaneous fungi.
AID376325Antifungal activity against Candida albicans isolate after 72 hrs by serial dilution technique2006Journal of natural products, Apr, Volume: 69, Issue:4
Linear sesquiterpene lactones from Anthemis auriculata and their antibacterial activity.
AID48265Tested In vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 5.82002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1596690Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by microdilution technique2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID601254Antifungal activity against Aspergillus fumigatus using 1 x 10'5 spore/100 uL after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID456068Antifungal activity against Aspergillus versicolor ATCC 11730 after 72 hrs by serial dilution method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1596684Antifungal activity against Aspergillus fumigatus ATCC 1022 after 72 hrs by microdilution technique2019European journal of medicinal chemistry, Aug-01, Volume: 175Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies.
AID456836Antifungal activity against Penicillium ochrochloron ATCC 9112 after 72 hrs by serial dilution method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID49263The compound was tested for percent resistance against Candida. albicans (40 clinical isolates) at 256 micro g/mL (pH=7.2), activity is expressed as R%.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID644187Antifungal activity against Fulvia fulva after 72 hrs by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID723703Fungicidal activity against Aspergillus flavus ATCC 9643 after 72 hrs by serial subcultivation method2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID601256Antifungal activity against Trichoderma reesei using 1 x 10'5 spore/100 uL after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID601260Antifungal activity against Aspergillus fumigatus using 1 x 10'5 spore/100 uL assessed as 99.5% fungal killing of original inoculum after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID456835Antifungal activity against Penicillium funiculosum ATCC 36839 after 72 hrs by serial sub-cultivation method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1184071Inhibition of mouse TDO expressed in mouse P815B cells using L-tryptophan substrate incubated for 24 hrs by HPLC based cellular assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID416217Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at epidermis at ED50 after 4 days by Uvitex-2B staining-based fluoresce2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID49269In vitro antifungal activity against 40 strains at pH 7.2 minimum inhibitory concentration2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1411635Antifungal activity against Aspergillus fumigatus after 72 hrs by serial dilution method
AID601262Antifungal activity against Trichoderma reesei using 1 x 10'5 spore/100 uL assessed as 99.5% fungal killing of original inoculum after 72 hrs by microdilution method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents.
AID1721994Fungicidal activity Penicillium funiculosum2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID322753Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay2007Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID1399510Fungicidal activity against Aspergillus versicolor ATCC 11730 after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID4911250% inhibitory activity against Candida albicans (40 clinical isolates) determined at pH-7.21995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents.
AID600777Fungicidal activity against Trichoderma viride IAM 5061 after 72 hrs2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID600772Antifungal activity against Fusarium sporotrichioides IMT 496 after 72 hrs by serial dilution method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID633958Antifungal activity against Aspergillus ochraceus ATCC 12066 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID49433In vitro antifungal activity against 40 strains at pH 7.2,(percent of resistant species at 256 ug/mL)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID1411646Fungicidal activity against Penicillium ochrochloron ATCC 9112 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs and measured after 72 hrs by serial dilution method
AID1411647Antifungal activity against Candida albicans after 72 hrs by serial dilution method
AID633959Antifungal activity against Aspergillus fumigatus isolated from human incubated for 72 hrs followed by serial sub-cultivation for 72 hrs by serial dilution technique2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.
AID48456Tested in vitro for antifungal activity against candida Spp (Candida glabrata, Candida krusei) at pH 7.2 (percent of resistant species at 256 ug/mL)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies.
AID416225Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at hypodermis at twofold ED90 after 4 days by Uvitex-2B staining-based 2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID1721991Fungicidal activity Aspergillus ochraceus2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID1721987Antifungal activity Penicillium ochrochloron by microdilution method2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID1399523Antifungal activity against Penicillium cyclopium var verucosum after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID774655Selectivity ratio of cytotoxic activity against mouse NIH/3T3 cells to antitrypanosomal activity against amastigote stage of Trypanosoma cruzi2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1283270Inhibition of CYP51 in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID644191Antifungal activity against Aspergillus fumigatus human isolate treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID456067Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial sub-cultivation method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID416233Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 infected in excised human skin assessed as inhibition of invasive colonized hyphal growth at hypodermis at ED50 after 4 days by Uvitex-2B staining-based fluorescenc2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID1399513Antifungal activity against Aspergillus niger ATCC 6275 after 72 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID1399516Fungicidal activity against Trichoderma viride IAM 5061 after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID235925Ratio of the in vitro minimal inhibitory concentrations to that of bifonazole against Candida albicans (MIC(compound)/MIC(bifonazole))2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
AID644188Antifungal activity against Penicillium funiculosum ATCC 36839 treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID249297In vitro concentration causing 50% inhibition of Candida albicans with percentage of resistant strains %R = 10 (MIC > 64 ug/mL) at a range of 0.5-8 ug/mL2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
AID600687Antifungal activity against Aspergillus ochraceus ATCC 12066 after 72 hrs by serial dilution method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.
AID1721996Fungicidal activity Penicillium verrucosum var. cyclopium2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID1411643Fungicidal activity against Trichoderma viride IAM 5061 incubated for 72 hrs followed by serial sub-cultivation for 72 hrs and measured after 72 hrs by serial dilution method
AID48927Tested for antifungal activity against azole resistant strain Candida albicans CIP 1760-88 after 48 hr incubation2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Stereoselective synthesis of 7 alpha- and 7 beta-aminocholestanol as potent fungicidal drugs.
AID1399518Fungicidal activity against Penicillium funiculosum ATCC 36839 after 144 hrs by serial dilution assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation.
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1721989Fungicidal activity Aspergillus fumigatus2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
New vinyl-1,2,4-triazole derivatives as antimicrobial agents: Synthesis, biological evaluation and molecular docking studies.
AID644192Antifungal activity against Aspergillus niger ATCC 6275 treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (284)

TimeframeStudies, This Drug (%)All Drugs %
pre-199087 (30.63)18.7374
1990's59 (20.77)18.2507
2000's58 (20.42)29.6817
2010's65 (22.89)24.3611
2020's15 (5.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.62 (24.57)
Research Supply Index5.87 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials49 (16.07%)5.53%
Reviews9 (2.95%)6.00%
Case Studies21 (6.89%)4.05%
Observational0 (0.00%)0.25%
Other226 (74.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]